CTTQ
Status and phase
Conditions
Treatments
About
To evaluate the efficacy and safety of TQ-B3139 in subjects with ALK-positive non-small cell lung cancer that have demonstrated progression during or after crizotinib treatment whether or not previously treated with cytotoxic chemotherapy.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
135 participants in 1 patient group
Loading...
Central trial contact
Li Zhang, Doctor
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal